Table 5.
Patients with residual cancer correctly identified by VAB
| N = 73 (%) | |
|---|---|
| Tumor subtype | |
| HER2+, HR− | 5 (6.8) |
| HER2+, HR+ | 28 (38.4) |
| TNBC | 40 (54.8) |
| Imaging modality used after NAST | |
| Mammography | 13 (17.8) |
| Ultrasound | 71 (97.3) |
| MRI | 2 (2.7) |
| Results of routine imaging after NAST | |
| ycT0 | 21 (28.8) |
| ycT+ | 52 (71.2) |
| ycN status | |
| ycN0 | 61 (83.6) |
| ycN+ | 6 (8.2) |
| Missing | 6 (8.2) |
| Histopathologic results | |
| ypT0, ypN0 | 0 (0) |
| ypT+, ypN0 | 57 (78.1) |
| ypT0, ypN+ | 0 (0) |
| ypT+, ypT+ | 16 (21.9) |
| ypT stage | |
| ypT0 | 0 (0) |
| ypT1a | 15 (20.5) |
| ypT1b | 13 (17.8) |
| ypT1c | 19 (26.0) |
| ypT2 | 14 (19.2) |
| ypT3 | 0 (0) |
| ypTis | 12 (16.4) |
HER2 human epidermal growth factor receptor 2, HR hormone receptor, TNBC triple-negative breast cancer, NAST neoadjuvant systemic treatment